Document Detail


Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
MedLine Citation:
PMID:  25183365     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Renal anemia of chronic kidney disease (CKD) is generally treated by erythropoiesis-stimulating agents (ESAs). However, there are individual differences in patients' responsiveness to ESA, which may affect the prognosis of CKD.
METHODS: The effect of ESAs on hemoglobin was followed in 297 CKD patients with renal anemia. Three types of ESA, epoetin alfa or beta, darbepoetin alfa, and epoetin beta pegol, were used in this study and dose of ESA was converted to that of epoetin using a dose conversion ratio (epoetin:darbepoetin alfa:epoetin beta pegol = 200:1:0.93). After initial 12-week administration of ESAs, the patients were divided into three groups: poor, intermediate, and good responders based on ΔHb/week/epoetin dose as an index. Hemoglobin values were followed for 144 weeks.
RESULTS: Initial patient characteristics-including age, body mass index, hemoglobin, estimated glomerular filtration rate, transferrin saturation, ferritin, albumin, calcium, parathyroid hormone, C-reactive protein, and urine protein-were similar in the three responder groups, except phosphate in the poor responder group was significantly higher than in the other two groups. The period from ESA use to renal death (RD) was significantly shortest in the poor responder group, and the number of RD patients was fewer in the good responder group. Multivariate Cox regression revealed that low final ΔHb(ΔHb from ESA use to just before dialysis)/week/epoetin dose, and low Hb after 12-week ESA use were significant factors related to responsiveness to ESA, suggesting that hyporesponsiveness to ESA was a risk factor for RD. Cox regression also found that hyperphosphatemia and diabetic nephropathy were risks for RD as well.
CONCLUSIONS: The study results suggest that hyporesponsiveness to ESA after the first 12-week administration as well as after 12 weeks is a risk for RD in pre-dialysis CKD patients. Furthermore, hyperphosphatemia and diabetic nephropathy are risk factors for RD.
Authors:
Michio Kuwahara; Shintaro Mandai; Yuri Kasagi; Keita Kusaka; Tomomi Tanaka; Satomi Shikuma; Wataru Akita
Related Documents :
25411995 - Evidence of crohn's disease-related anti-glycoprotein 2 antibodies in patients with cel...
25438855 - Factors that influence kidney shear wave speed assessed by acoustic radiation force imp...
910805 - Intracranial tumors simulating the presentation of cerebrovascular syndromes. early det...
6131165 - Do patients with cerebral malaria have cerebral oedema? a computed tomography study.
10592355 - Prescription of twice-weekly hemodialysis in the usa.
3491655 - Effects of thalamic stroke on energy metabolism of the cerebral cortex. a positron tomo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-9-3
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  -     ISSN:  1437-7799     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-9-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Empowering the child and caregiver: yellow zone asthma action plan.
Next Document:  Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulat...